Humacyte’s (HUMA) “Buy” Rating Reiterated at Benchmark

Benchmark reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report released on Thursday,Benzinga reports.

Several other research analysts also recently commented on the company. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Up 0.9 %

Shares of HUMA opened at $3.40 on Thursday. The company has a market capitalization of $427.92 million, a PE ratio of -2.54 and a beta of 1.30. Humacyte has a 12 month low of $2.81 and a 12 month high of $9.97. The stock’s 50-day moving average price is $4.36 and its two-hundred day moving average price is $4.95.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. bought a new stake in shares of Humacyte during the 4th quarter valued at about $50,000. Petros Family Wealth LLC bought a new stake in shares of Humacyte during the 4th quarter valued at about $50,000. Syon Capital LLC bought a new stake in shares of Humacyte during the 4th quarter valued at about $54,000. Brookstone Capital Management bought a new stake in shares of Humacyte during the 4th quarter valued at about $56,000. Finally, ACT Wealth Management LLC bought a new position in Humacyte in the fourth quarter worth approximately $57,000. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.